1.. INTRODUCTION
================

NBN (formerly known as NBS1) is a protein of 754 amino acid composed of three regions: the *N*-terminus (containing a forkhead associated domain (FHA) and two breast cancer 1 (BRCA1) carboxy-terminal (BRCT) tandem domains), a central region (containing sites phosphorylated by the Ataxia-Telangiectasia Mutated (ATM) kinase), and the *C*-terminus (containing the MRE11- and ATM-binding domains) \[[@R1]-[@R11]\]. The NBN protein is a member of the MRE11/RAD50/NBN (MRN) complex, which is involved in nearly all aspects of the DNA double-strand break (DSB) metabolism, from lesion recognition, to DNA repair by both non-homologous end-joining (NHEJ) and homologous recombination repair (HRR) pathways, to cell cycle control \[[@R12]-[@R18]\]. Remarkably, DNA damage may arise as the consequence of physiological cellular metabolism or produced by the exposure to environmental pollutants \[[@R19]-[@R21]\]. As a consequence of the pivotal role of the MRN complex in the maintenance of genomic stability, any genetic variation of the *NBN* gene may have detrimental effects on cells capability to properly face with DNA damage, and consequently may predispose to cancer and to the genetic disease named Nijmegen Breakage Syndrome (NBS) \[[@R13],[@R22]-[@R24]\].

NBS is an autosomal recessive disorder characterized by microcephaly, immunodeficiency, spontaneous chromosomal instability, sensitivity to ionizing radiations and a high incidence of malignancy \[[@R25]-[@R27]\]. Cancer, and in particular malignancy of lymphoid origin, is the primary cause of death among NBS affected individuals. More than 70% of the malignancies were non-Hodgkin lymphoma \[[@R28]-[@R32]\], though solid tumours as medulloblastoma \[[@R33]-[@R35]\], rabdomiosarcoma of the perianal region \[[@R36]\], melanoma \[[@R37]\], breast \[[@R38]-[@R41]\], prostate \[[@R42]\], ovarian \[[@R43]\], lung \[[@R44]\] and colorectal cancers \[[@R45]\] were also represented.

The most common *NBN* mutation is due to the deletion of five base pairs (bps) in exon 6 (657del5), which leads to protein truncation. In addition to this mutation, which affects mostly Central Europe populations, at least 11 other truncating and missense mutations have been reported so far in NBS patients \[[@R2],[@R46]-[@R53]\]. Interestingly, some evidences point to a possible correlation between cancer risk and *NBN*at the heterozygous status, as it occurs in blood relatives of NBS patients \[[@R22],[@R23]\]. Furthermore, such a relationship has been corroborated by additional studies which identified carriers for the *NBN*657del5, R215W and I171V mutations overrepresented in cancer patients \[[@R23],[@R30]-[@R32],[@R37],[@R41],[@R54]-[@R62]\]. The observation that in tumors recovered from NBN carriers the inactivating mutation was not detected on the second allele, seems to suggest a dominant negative mechanism. Such an effect in *NBN* monoallelic mutated tumors could be due to truncated NBN proteins as result of an alternative NBN translation \[[@R9],[@R63]\].

2.. *NBN* SINGLE NUCLEOTIDE POLYMORPHISMS AND CANCER RISK
=========================================================

Beside classical miscoding mutations associated with either clinical signs of the NBS disorder or a functionally alterated NBN protein, a certain number of both low- and high-frequency polymorphisms have been reported to be distributed over the 16 exons of the *NBN* gene. According to the Environmental Genome Project (EGP), so far 675 single nucleotide polymorphisms (SNPs) have been reported for the *NBN* gene \[[@R64]\]. Among them, 84 are considered common based on a minor allele frequency of \>5% \[[@R65]\]. As for *NBN* mutations, also for *NBN* gene polymorphisms acting as slow-penetrance genes a possible association with different kinds of malignancy has been evaluated in the last 15 years, in that DNA polymorphisms may bring to subtle structural alterations of proteins and consequently modulation of cancer susceptibility. In (Table **[1](#T1){ref-type="table"}**) is reported a list of a selected panel of *NBN* genetic variants, their effects on amino acid change, and their localization into protein's domains.

Here we provide the reader with the state of the art on this topic, limiting the attention to SNPs of the sole *NBN* gene, though in many of the presented works a large panel of polymorphisms in gene involved in DNA repair, cell cycle control, and metabolism of genotoxics was also investigated. The risk of cancer associated with *NBN* SNPs appears to differ by cancer type. In particular, based on the published papers, the association of *NBN*SNPs has been restricted to a panel of hematological and solid tumors (Table **[1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}**).

2.1.. Basal Cell Carcinoma
==========================

Basal cell carcinoma (BCC) is considered the most common neoplasia of the skin, accounting for more than 75% of all skin malignancies \[[@R66],[@R67]\]. Though locally invasive and slow-growing, BCC is characterized by recurrence and tissue destruction \[[@R68]\]. Regarding the etiology of BCC, it has been proposed that both genetic factors and environmental determinants, as exposure to ultraviolet (UV) radiation, may contribute to the development of this kind of cancer \[[@R69],[@R70]\]. Therefore, genes whose products are enzymes involved in the removal of DNA lesions introduced by UV-light exposure may play a critical role in the etiology of BCC. In this respect, non-synonymous SNPs known for their potential capability to modulate gene functions are worth to be analysed \[[@R71]\].

The association of the rs1805794 *NBN*genetic variant with BBC risk was assessed in two case-control studies on Caucasian individuals in Europe. The first one comprised cohorts of patients (241) and controls (574) from Sweden and Finland \[[@R72]\]. Genotype distributions for the common rs1805794 variant were in accordance with those expected from Hardy-Weinberg equilibrium. No differences between controls and carriers of the rs1805794 *NBN*variant were observed with respect to BCC risk \[[@R72]\].

The second study, considered one of the largest association study, was conducted on a cohort of 529 BCC patients from Central Europe countries (*i.e.*, Hungary, Romania, and Slovakia) and 533 matched healthy control individuals \[[@R73]\]. Also in this study, the only polymorphism analyzed for a possible association with BCC was the rs1805794. No deviation from Hardy-Weinberg equilibrium distribution was detected for cases and controls. Interestingly, the authors found a gender relationship between the *NBN* SNP and BCC, in that in men homozygous for the C-allele an odd ratio (OR) of 2.19 (95% CI, 1.23-3.91) was calculated, whereas in women the calculated OR was 0.84. In addition, a multiplicative gene-gene interaction effect was found on the BCC risk association among men carrying the genotype CC *XRC3*/CC *NBN*, with an OR reaching the value of 8.79 (95% CI, 2.10-36.8), compared to the genotype TT *XRC3*/GG *NBN* \[[@R73]\].

2.2.. Bladder Cancer
====================

Urinary bladder cancer ranks ninth in worldwide cancer incidence, and particularly it represents the seventh most common malignancy in men and the seventeenth in women \[[@R74]-[@R77]\]. Some risk factors for bladder cancer have been recognized in environment exposure to aromatic amines, cigarette smoking exposure and uptake of several compounds as phenacetin and cyclophosphamide \[[@R78],[@R79]\]. However, a growing body of evidence has emerged indicating that culture-mediated and socioeconomic factors contribute substantially to the etiology of bladder tumors and may play an even more important role than the occupational environment \[[@R80]\].

The exposure to environmental agents and by-products of cellular metabolism results in DNA damage, which, if left un-repaired, can lead to carcinogenesis \[[@R81],[@R82]\]. A certain number of studies have been conducted in order to establish an association between urinary bladder cancer risk and genetic polymorphisms for a large panel of genes involved in DNA repair (*e.g.*, *BRCA1*, *RAD51*, *XPC*, *XPD*, *XRCC1*, *XRCC2*, *XRCC3*, *XRCC4*, etc), in the metabolism of genotoxic carcinogens (*e.g.*, *GSTT1*, *NAT1*, *NAT2*, *NQO1*, *MTHFR*, etc), and in cell cycle control (*e.g.*, *cyclin D1*) \[[@R83]-[@R93]\]. In particular, only few studies have analyzed the possible role of the *NBN* genetic variants in cancer susceptibility. In a case-control study in which 299 Caucasian bladder cancer patients from hospitals in the Stockholm area and 278 matched controls were gathered, the genotype distribution of SNPs was in accordance with Hardy Weinberg equilibrium, and the frequency of the common rs1805794 SNP in CC homozygous condition, between healthy controls and bladder cancer cases indicated a marginal significant difference (OR 1.64, 95% CI, 0.92-2.90, P=0.09) \[[@R82]\]. No association was detected between 1086 Caucasian bladder cancer patients and 1020 controls with respect to four *NBN* genetic variants (*i.e.*, rs1063045, rs1805794, rs867185, rs1063053) \[[@R88]\]. Similarly, in a case-control study on 771 bladder cancer cases and 800 controls of both Caucasian and non-Caucasian ethnicity, the association of bladder cancer risk with nine NBN variants, located at the 3'-UTR (*i.e.*, rs14448, rs9995, rs13312986, rs1063054, rs13312981, rs2735383, rs1063053) and in coding regions (*i.e.*, rs1805794, rs769420) was evaluated \[[@R90]\].

2.3.. Breast Cancer
===================

Brest cancer is the most common form of cancer among women, for which both genetic and environmental factors have been reported \[[@R94]\]. Although the cause of breast cancer is still obscure in the majority of cases, for a significant fraction of cases the age at the first child's birth and the family history represent well-established risk factors \[[@R95]\]. Remarkably, it has been also reported that breast cancer patients might be deficient in the repair of DNA damage \[[@R96]\]. Indeed, approximately 5% to 10% of breast cancers are

related to an inherited gene mutation. Of these cases, 84% of hereditary breast cancers and more than 90% of hereditary ovarian cancers are caused by mutations in either *BRCA1* or *breast cancer 2*(*BRCA2*) genes. Familial aggregation involving genes other than *BRCA1* and *BRCA2* seems to be the result of the additive effect of multiple low penetrant genes \[[@R97]\]. Overall, pathogenic mutations in *TP53, ATM, CHEK2, BRIP1*and*PALB2*, together with *BRCA1* and *BRCA2* mutations, account for less than 20-25% of the excess familial risk of breast cancer, thus supporting the notion that also other cancer susceptibility genes may play a role in the pathogenesis of breast cancer. Based on the recognized role of both BRCA1 and BRCA2 in different aspects of DSBs damage response and repair \[[@R98]\], many association studies have been carried out with respect to genes involved in the NHEJ and HRR repair, and particular between *NBN* and breast cancer risk. Indeed, several SNPs identified in genes involved in the HRR pathway (*e.g.*, *XRCC2*, *XRCC3*, *NBN,* and *RAD51*) may influence the repair capacity of breast cancer patients and, in turn, confer genetic predisposition to disease \[[@R99]\].

In this respect, any association for the rs1063045, rs1805794, rs709816, and rs1061302 *NBN* SNPs was found in 2205 Caucasian patients and 1826 controls (age range 45-74 years) \[[@R100]\]. In a similar way, no association was found between the rs1805794 polymorphism and breast cancer risk in another hospital-based study performed on 766 African-American (681 matched controls) and 1273 Caucasian women with breast cancer (1136 matched controls) (age range 21-74 years) \[[@R101]\].

In a series of other relatively small studies, conducted on 221 Finnish sporadic breast cancer patients and Poland familial cases \[[@R102]\], 220 Chinese population patients \[[@R103]\], 336 Caucasian patients \[[@R104]\], 97 cases selected from high-risk families from the French-Canadian population \[[@R105]\], and 289 Caucasian Portuguese patients \[[@R95]\], no association between the rs1805794 and breast cancer risk was reported.

On the contrary, a certain number of studies pointed to a significant association between *NBN* gene variants and sporadic breast cancer risk. A study carried out in the genetic homogeneous Taiwanese population analyzed the rs1805794, rs1805790, rs709816, rs1061302, and rs1063045 SNPs of the *NBN*gene in 559 female breast cancer patients and 1125 healthy female controls \[[@R106]\]. In this study, a significant 1.29-fold increase in risk (95%, CI 1.00-1.69) was reported for the only rs1805790 variant in the form of the GG homozygous genotype \[[@R106]\].

The rs36226237 promoter variant was found significantly increased in a cohort of 97 high-risk non-*BRCA1* and non-*BRCA2* breast cancer families from the French-Canadian population compared with 74 unrelated healthy controls from the same origin \[[@R105]\]. In another study, the rs1805794, 924T\>C^\*^, and 30537G\>C[\*](#FN1){ref-type="fn"} *NBN* genetic variants were analyzed in a hospital-based case-control study of 421 relatively young non-Hispanic Caucasian women (≤55 years: range 22-55 years). An association of the variant rs1805794GG (in an allele-dose response manner; GC OR: 1.33, 95% CI 1.00-1.78; CC OR: 1.83, 95% CI 1.14-2.94) and of carriers of the homozygote rare variant 924CC (OR: 4.55, 95% CI 1.51-13.7) with breast cancer risk was found \[[@R107]\]. Such an association was also found for haplotype analysis in allele/dose response manner, but not for the 30537G\>C polymorphism. A similar result, showing a significant trend of breast cancer risk with increasing numbers of GC/CC genotypes of the rs1805794 variant in a very small sample of African-American patients (63 cases and 78 controls) was reported \[[@R104]\].

[^1]

2.4.. Colorectal Cancer
=======================

Colorectal cancer is a common neoplasia in both men and women, and ranks as the second worldwide \[[@R108],[@R109]\]. In the last decades the incidence is greatly increased in Europe, and in particular in the central Europe region, with Czech Republic having the highest rate in the world for rectal cancer and the third highest incidence for colorectal cancers \[[@R109]-[@R111]\]. Colorectal cancer may occur in three different forms, and namely: the sporadic form (about 85% of cases), the familial form (less than 10%) and the form transmitted as a Mendelian trait (5%), which include familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC) \[[@R112]\]. In the etiopathology of the sporadic form of the malignancy, both genetic and environmental factors, as diet, drinking and smoking habits, seem to play a relevant role \[[@R113],[@R114]\]. Other factors (*e.g.*, genetic variants with low penetrance) may be involved in the modulation of colorectal risk. Indeed, with respect to a possible association between *NBN*polymorphisms and the risk of colorectal cancer, only one case-control study carried out in 532 Caucasian cases and 532 control in Czech Republic and restricted to the rs1805794 *NBN* genetic variant was found in the literature \[[@R111]\]. Genotype frequencies in control cases were tested for their accordance with Hardy-Weinberg expectation. The OR for the three genotypic combinations of the *NBN* SNP showed no association with the risk of colorectal cancer \[[@R111]\].

2.5.. Head and Neck Tumors
==========================

Excluding skin and thyroid cancers, virtually all carcinomas that occur in the head and neck region arise within the upper aerodigestive tract and connected adenexal structures. Taken together, carcinomas of the upper aerodigestive tract, also termed head and neck cancer, account for only 3.2% of all incident malignancies in the United States \[[@R115]\] and for approximately 5% of all newly diagnosed cancer cases in the northern and Western European countries \[[@R116]\]. The overwhelming majority of these head and neck cancers are head and neck squamous cell carcinomas (HNSCC) with most of the remainder being salivary gland carcinomas. To better understand etiologic associations and clinical management/outcomes, head and neck cancers are subcategorized by their site of origin and annually account for approximately 17,000 cancers of the oral cavity, 10,000 of the larynx, 10,000 of the oropharynx, and 2500 of the hypopharynx \[[@R115],[@R117],[@R118]\]. Despite recent advances in the diagnosis and treatment of HNSCC, survival rates of patients affected by these tumors still remain at low levels (40% to 50%) \[[@R116]\]. Smoking and alcol drinking are recognized as relevant factor in the development of HNSCC, though some genetic factors have been invoked to explain individual differences in susceptibility. In a study carried out on 175 Polish men patients with a single laryngeal cancer (*i.e.*, 104 patients with multiple tumors in the larynx and 60 patients with multiple primary tumors localized in the head and neck region excluded laryngeal cancer) together with 275 healthy controls, a possible association between 6 *NBN* SNPs and head and neck cancer risk was tested \[[@R116]\]. The *NBN* genetic variants analysed were both synonymous and non-synonymous (*i.e.*, rs1063045, rs1805794, rs2234744, rs709816, rs1061302, rs3736639). The genotypes distributions were tested for its accordance with Hardy-Weinberg expectation. The frequency of the *NBN* rs1805794 variant genotype at the GC heterozygous status was significantly lower in laryngeal cancer (OR: 1.79, CI 95%, 1.18-2.70, p=0.0055) and multiple cancer patients (excluded laryngeal cancer) with respect to normal controls (OR: 2.03, CI 95%, 1.09-3.78, p = 0.0234). In a similar way, the C allele (GC+CC) was less represented in patients with laryngeal tumor (49% versus 60% in controls, p=0.029, OR 1.52). The rs2234744 SNP frequency was 48% CT and 62% CT+TT in controls vs 30% CT and 15% CT+TT in patients with multiple cancer patients (excluded laryngeal cancer). The calculated differences were statistically significant with an OR value of 2.28 (p=0.008) and 1.97 (p=0.016), respectively. The heterozygous genotype AG of the rs1061302 variant was more common in controls (46%) than in patients affected with laryngeal cancer (34%; OR: 1.65, 95% CI 1.09-2.50, p=0.017). Similar was the situation for the AT genotype of the rs3736639 which was more represented among controls (47%) compared with laryngeal cancer group (34%, OR: 1.64, 95% CI 1.08-2.48, p= 0.018). On the contrary, no association between the remaining *NBN* polymorphisms and the three groups of patients were found \[[@R116]\].

Among head and neck cancers, nasopharyngeal carcinoma (NPC) is considered a leading cause of death in South China, and is characterized by a high incidence of nodal and distant metastasis \[[@R119]\]. Beside environmental factors as drinking, smoking, nitrosamines, and salty food, the main etiological factor seems to be Epstein-Barr virus infection \[[@R120]-[@R125]\]. Individual genetic susceptibility in genes devoted to the maintenance of genome stability has been invoked as a possible contributor in the development of NPC. A multiple-center case-control study was performed to assess the association between the rs1805794 and rs2735383 (located at the 3'-UTR of*NBN*) SNPs and NPC risk in 1052 ethnically homogeneous cases drawn from the Eastern and Southern Chinese population and 1168 controls \[[@R126]\]. Hardy-Weinberg equilibrium was tested, but it did not reveal differences between observed and expected genotype frequencies. Genotyping results showed a significant association of the miscoding rs1805794 variant with the NPC risk in both the Chinese populations \[[@R126]\]. The OR values for the homozygous rare allele CC and the heterozygous GC one were 1.73 and 3.75, respectively, compared with the GG genotype in the Eastern Chinese population (p\<0,001). In the Southern population the OR values were 1.51 (95% CI 1.09-2.15, p\<0.001) and 3.91 (95% CI 2.53-6.20, p\<0.001). Overall, while an allele-dose response association between the rs1805794 SNP with NPC cancer risk was found, no association was detected for the 3'UTR *NBN*polymorphism \[[@R126]\].

2.6.. Hepatic Cancer
====================

Hepatocellular carcinoma (HCC) is the most common form of liver cancer, representing 70% to 85% of primary hepatic malignancies in adults. HCC is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected \[[@R127]\]. The incidence of HCC is increasing, likely attributable to the increased prevalence of hepatitis C and possibly nonalcoholic fatty liver disease \[[@R128]\]. The incidence of HCC is highest in Asia and Africa, where the endemic high prevalence of hepatitis B and hepatitis C strongly predisposes to the development of chronic liver disease and subsequent development of hepatocellular carcinoma \[[@R127],[@R129]\]. Indeed, a large cohort of patients infected with hepatitis C several decades ago are now expected to seek medical care and present with complications of cirrhosis \[[@R130]\]. Because HCC tends to arise in the setting of cirrhosis, liver transplant is the ultimate life-saving modality because it removes the diseased liver along with macroscopic and microscopic cancer cells \[[@R131]\]. Although there is a growing understanding of the molecular mechanisms that induce hepatocarcinogenesis, real mechanisms of hepatocarcinogenesis have not been completely elucidated. However, cumulative knowledge regarding the molecular mechanisms of carcinogenesis revealed that the development and progression of HCC are caused by the accumulation of genetic changes, thus resulting in altered expression of cancer-related genes \[[@R129]\].

To our knowledge only a paper was devoted to the investigation of the association between genetic variations in the *NBN* gene and HCC risk. The study was carried out in an ethnically homogenous Chinese population of 865 HCC patients and 900 cancer-free healty controls looking at the rs1805794 and rs2735383 variants \[[@R132]\]. It was found that the rs1805794 SNP was associated with increased risk of developing HCC malignancy in an allele-dose response manner, in particulare the GC genotype presented an OR value of 1.41 (95% CI 1.11-1.80), whereas the CC carriers had an OR of 2.27 (95% CI 1.68-3.14). In addition the risk effect was more pronounced in ever-drinking HCC patients. On the contrary, no association was detected for the rs2735383 3'UTR *NBN*polymorphism \[[@R132]\].

2.7.. Lymphoma and Acute Lymphoblastic Leukemia
===============================================

Lymphoid cancer and leukemia are common malignancies in childhood \[[@R54],[@R133]-[@R137]\] associated with specific chromosomal translocations, as immunoglobulin and T-cell receptor loci or rearrangements involving chromosomes 9 and 22 \[[@R138]-[@R140]\]. Translocations occur as result of incorrect processing of DSBs produced during antigen receptor rearrangements, physiological processes, and as an effect of clastogenic agents as ionizing radiations or chemotherapeutic agents \[[@R141]-[@R144]\]. Therefore, processing of DNA lesions arising physiologically or as response to DNA damaging agents is a critical step for the maintenance of genome stability. As a consequence, alterations in genes, as *NBN*, whose products taking active part in DNA damage repair may led to misrepair and chromosomal aberrations which in turn contribute to cancer development \[[@R13],[@R23]\].

Several studies have been carried out to evaluate the potential role of the *NBN* SNPs and hematological malignancies. In a study performed in the United States on 91 cases of sporadic Non-Hodgkin lymphoma (NHL) (B-cell and T-cell origin) and 154 controls, the frequencies of six common *NBN*polymorphisms (*i.e.*, rs1063045, rs1805794 rs2234744, rs709816, rs2308962, rs1061302) were analyzed and no association with lymphoid tumors was found \[[@R28]\].

No association between NHL and the *NBN* variants rs13312842, rs36226237, rs1805796, rs1063053, rs1063045, rs1805794, and rs1061302 was reported in a Canadian study carried out on 797 cases with an ethnical background that included Caucasian, Asian, South Asian, mixed populations and 793 matched controls \[[@R145]\]. Coding and non-coding DNA was sequenced, as well as 1000 bps upstream of the transcription start, and no association between NHL risk and seven *NBN* polymorphisms was found \[[@R145]\]. In a similar way, in another study no association was detected for the rs1805794 variant in 200 Hodgkin lymphoma (HL) patients and 220 controls, though in combination allelic variants in *XPC, XRCC1, XRCC3*and*NBN* genes modified the risk of developing HL \[[@R146]\].

Regarding leukemia, it should be recalled that in children about 80% are acute lymphoblastic leukemia (ALL) \[[@R54],[@R134],[@R144],[@R147]\]. To study whether *NBN* polymorphisms may influence susceptibility to the development of childhood ALL, a case-control study has been carried out in 157 Polish children and 275 controls \[[@R148]\]. Six SNPs of the *NBN* gene have been analyzed (*i.e.*, rs1063045, rs1805794 rs2234744, rs709816, 1061302, rs3736639). Genotype frequencies distributions were in accordance with Hardy-Weinberg equilibrium. The only rare homozygous TT genotype of the rs3736639 variant was found to slightly increase in frequency among leukemia patients as compared to controls (OR: 1.82, 95% CI 1.00-3.32, p=0.04). No significant differences in both allele and genotypes frequencies were detected for the remaining five *NBN* polymorphisms \[[@R148]\].

Apart from the studies on the Caucasian populations, some studies on the association between *NBN* polymorphisms and risk of hematological malignancies have been performed in the Chinese population. Regarding ALL risk (both B-ALL and T-ALL), in a recent study conducted on 175 Chinese patients and 360 controls, an association with the rs1805794 variant was found, but not for the rs2735383 3'UTR SNP \[[@R65]\]. In particular, the C allele frequency was higher among patients (0.61) than in controls (0.40). Genotypic frequencies did not deviate from the expected Hardy-Weinberg equilibrium distributions. The frequencies of the three genotypic combinations (*i.e.*, GG, GC and CC) differed significantly from those observed in healthy controls (p\<10^-5^). In addition, carriers of the homozygous CC genotype presented an OR value of 3.4 (95% CI 1.47-8.01 p\<0.0001) compared to the GG genotype \[[@R65]\].

In another Chinese hospital-based case-control study, the association between the rs1805794 and rs2735383 (located at the 3'-UTR of *NBN*) polymorphisms and acute myeloid leukemia (AML) risk was investigated in 428 ethnically homogeneous AML patients and 600 cancer-free controls \[[@R149]\]. Genotypes were distributed in accordance with Hardy-Weinberg equilibrium. The genotypic frequencies of the rs1805794 variants GG, GC and CC significantly differed between patients and controls. With respect to the rare homozygous CC genotype taken as reference, both GC and GG genotypes were associated with a significantly decreased risk of AML (OR: 0.5, 95% CI 0.37-0.67, p\<0.0001 for GC genotype; and OR: 0.23, 95% CI 0.16-0.34, p\<0.0001 for GG genotype). In addition, the C allele frequency was 56.8% in healthy controls and 39.3% in patients (p\<0.0001). Overall, it was found that for the rs1805794 variant the genotypes GC+GG appeared to be protective against AML, and that the risk decreased as the number of G alleles increased. On the contrary, the 3'- UTR *NBN*polymorphism was not associated with AML \[[@R149]\].

The association between ALL and *NBN* haplotypes for the rs12680687, rs6470522, rs7840099, and rs709816 variants in both Hispanic and non-Hispanic ethnicity and matched controls was examined \[[@R144]\]. They found significant ALL cytogenetic subtype-specific *NBN*haplotype association with t(12;21) positive childhood ALL \[[@R144]\]. In addition, it was found that at least the rs709816 variant significantly influences the risk of second neoplasm after the treatment of childhood ALL \[[@R150]\].

2.8.. Lung Cancer
=================

Lung cancer is one of the most common cancers \[[@R151]\], and its incidence has increased generally worldwide during the last few years, especially in Asian countries \[[@R151],[@R152]\]. Though many advances in the treatment of lung cancer, it is still one of the leading causes of cancer mortality \[[@R153]-[@R156]\]. There are several types of lung cancers, including non-small cell lung cancer, small cell lung cancer, and lung adenocarcinoma \[[@R156],[@R157]\]. Currently, it is well accepted that lung cancer is a multi-factorial process that involves both environmental carcinogens and genetic factors \[[@R158]\]. Polymorphisms of genes involved in the repair of DNA damages caused by environmental carcinogens may be responsible for the hosts' susceptibility to cancers, since they affect the genetic susceptibility to carcinogens \[[@R159]\].

Several studies are available in the literature on the possible association between *NBN* gene polymorphisms and lung cancer risk. In a three-case control study investigating smoking-related cancers, including lung cancer (611 and 1040 controls of mixed ethnicity), an OR value of 1.6 (95% CI, 1.2-2.4) was found for the rs1061302 synonymous variant at the homozygous status \[[@R160]\]. Additionally, a positive correlation was found for the homozygous rs1063054 SNP located in the 3'-UTR region with lung cancer (OR: 1.6, 95% CI 1.0-2.3). Furthermore, the association was modified by the smoking status of patients, thus suggesting a role of *NBN* variants in tabacco-related carcinogenesis \[[@R160]\]. In an other study carried out in 109 lung cancer patients of mixed origin it was found that the prevalence of *TP53* mutations was significantly higher among individual homozygous for the rs1805794 NBN variant than among individuals for the wild-type allele \[[@R161]\]. A similar association between the rs1805794 variant and the prevalence of of *TP53* mutations in lung tumors has been also reported by \[[@R162]\].

More recently, the association between SNPs located in the 3'-UTR region of the *NBN* gene and lung cancer risk was investigated in Southern and Eastern Chinese populations \[[@R64]\]. In particular, three SNPs have been genotyped (*i.e.*, rs2735383, rs13312986, rs14448) in two independent hospital-based case-control studies conducted in the Chinese population. While no association was detected for both rs13312986 and rs14448 in 1559 patients and 1679 controls, the CC homozygous genotype of the rs2735383 SNP was significantly associated with cancer risk under a recessive genetic model (OR: 1.4, 95% CI 1.18-1.66, p=0.001). For this variant, the OR value rose to 1.7 in never-smokers (95% CI 1.34-2.17, p=1.3x10^-5^) \[[@R64]\].

2.9.. Medulloblastoma
=====================

Medulloblastoma is known to be the most common form of cancer of childhood, and consists of a highly malignant and invasive embryonic tumor of the cerebellum \[[@R163]-[@R165]\]. Although the majority of medulloblastoma occur sporadically, some of them occur within familial cancer syndromes, including the nevoid basal cell carcinoma (Gorlin syndrome) associated with germ-line *PTCH* mutations \[[@R166]\] and the Turcot syndrome type 2 caused by germ-line *APC* mutations \[[@R167]\].

In a study on 42 cases of medulloblastoma screened for *NBN*gene mutations, it was found that seven of them (corresponding to the 17%) carried a total of 15 *NBN*mutations: 10 missense point mutations and five intronic splicing mutations. Regarding miscoding mutations and SNPs, no differences in the frequencies detected in healthy controls and reported in the literature were observed for common variants (*i.e.*, rs1063045, rs709816, rs1061302, rs1805794) and intronic SNPs (*i.e.*, rs2234744, rs1805818, rs2308962), as well as for a rare intronic SNP (*i.e.*, rs3736640) \[[@R168]\]. However, neither genotype frequencies were reported nor was specified the ethnic characteristics of both the investigated patients and the reference healthy medulloblastoma-free population \[[@R168]\].

2.10.. Melanoma
===============

Skin melanoma is known for its extreme aggressivity, and its frequency is increased progressively in the last few years. Mutations in high-penetrance genes, *i.e.* *CDKN2A* and *CDK4*, have been identified as responsible for about 10% of all cases \[[@R37]\]. On the other hand, the genetic factors involved in the etiology of sporadic forms of melanoma are largely unknown \[[@R169]\] and the contribution of multiple low-penetrance and modifying genes has been proposed \[[@R170]-[@R177]\].

In a single study, the association of the *NBN*genetic variants with melanoma risk was analyzed in 376 Southern German patients \[[@R37]\]. By gene sequencing, three non-synonymous sequence variations within exon six of *NBN* were identified, that is V210F, F222L and R215W. Remarkably, the latter variation has been recognized as a true mutation since observed in compound heterozygosis with the classical 657del5 in two German twins affected by NBS \[[@R178]\]. Furthermore, in the same study reported above, a case-control study conducted on 632 melanoma patients and 615 controls of Southern Germany was performed, looking at three *NBN* SNPs (*i.e.*, rs9995, rs867185, rs1063045). No statistically significant association was found with melanoma risk for both the three SNPs and the different combination of haplotypes \[[@R37]\].

2.11.. Ovarian Cancer
=====================

Epithelial ovarian cancer is the most lethal gynecologic malignancy, which accounts for up to 5% of all cancer types among women \[[@R179]\]. The origin and pathogenesis of epithelial ovarian cancer remains not fully understood, though epidemiological evidences point to a role of the ovulation process, that consists in the epithelial cellular proliferation necessary to repair the wound, with the consequent risk of DNA lesions accumulation connected to an increased cellular division \[[@R180],[@R181]\].

In the literature, we have found only one study devoted to assess the association of *NBN*polymorphisms with invasive epithelial ovarian cancer risk \[[@R182]\]. In a case-control study performed on Caucasians gathered from four separate genetic association studies and from three countries, four common *NBN*SNPs (one having functional effects (*i.e.*, rs1805794) and three non-coding variants (*i.e.*, rs1063045, rs709816, rs1061302)). Genotypes frequency in controls did not differ significantly from an Hardy-Weinberg equilibrium. No evidence for an association of the four SNPs with epithelial ovarian cancer was detected \[[@R182]\].

2.12.. Prostate Cancer
======================

Prostate cancer is one of the most common non-cutaneous malignancy among men of the Western countries \[[@R183]\]. Some factors, as increasing age, African-American ancestry, diet, obesity and environmental pollutants have been proposed as risk determinants for prostate cancer, though familial aggregation and family-based linkage studies suggest that genetic factors may also be involved in this pathology \[[@R184],[@R185]\].

To our knowledge, the number of studies devoted to the analysis of association between *NBN* genetic variants and such kind of cancer is very limited. In a study carried out by the International Consortium for Prostate Cancer Genetics, which collected samples from five centers, 1809 familial and 1218 sporadic cases of prostate cancer were analysed for *NBN* mutations \[[@R57]\]. The *NBN*gene sequencing in a subset of 20 of the youngest individuals from the Finnish group of familial cases, allowed the identification of the common rs1805794 SNP. However, the analysis of 200 patients failed to show any association of rs1805794 variant with prostate cancer \[[@R57]\].

In a recent case-control study comparing 239 Caucasian patients from Portugal diagnosed with early prostate cancer and 186 patients who presented advanced disease, the rs1805794 SNP was investigated \[[@R186]\]. It was found that the GG carriers presented an almost two-fold increased risk for developing prostate malignancy (OR: 1.87, 95% CI 1.26-2.79, p= 0.002), thus suggesting a possible role for *NBN*in prostate cancer progression \[[@R186]\]. However, in this study, no mention was made to a reference control population.

2.13.. Renal Cell Carcinoma
===========================

Among all the malignancies of the genito-urinary apparatus, renal cell carcinoma (RCC) represents the third cause of death. In United States approximately 51,000 people were diagnosed with RCC in 2007, and roughly one third of these patients will ultimately die from this disease \[[@R115]\]. Many and different factors have been identified as contributors of RCC development, including gender, obesity, smoking, analgesic and diuretic abuse, and environmental factors \[[@R187]\]. Host factors have been invoked to explain tumor development inter-individual differences that may be attributed to SNPs in genes involved in the repair of DNA damage induced by carcinogens \[[@R188],[@R189]\].

To our knowledge, only one study has been published on the role of *NBN*genetic variants and RCC \[[@R190]\]. A population-based case-control study that included 326 Caucasian RCC patients and 335 matched cancer-free controls has been carried out to evaluate the association of 13 SNPs in 10 candidate genes of the DSBs repair pathway \[[@R190]\]. Among the selected SNPs, the rs1805794 *NBN* variant was investigated. This SNP was reported to be in Hardy-Weinberg equilibrium. A significantly increased frequency of the minor homozygous variant CC genotype was found to be associated with an increased risk of RCC (OR: 2.13, 95% CI 1.17-3.86, p=0.01). Interestingly, the cancer risk increased as increased the number of adverse alleles for both the rs1805794 variant of *NBN* gene and the rs1805377 variant of the *XRCC4*gene \[[@R190]\].

2.14.. Thyroid Cancer
=====================

Thyroid cancer is the most frequent endocrine neoplasia, with nonfamilial papillary and follicular thyroid carcinomas being the most common histological subtypes. These two histological subtypes are two to four times more frequent in women than in men, thus making thyroid cancer the eighth most prevalent cancer in women \[[@R191]\]. Exposure to ionisng radiation (IR) is the only established cause of thyroid carcinogenesis in humans \[[@R192]-[@R194]\], although other factors have also been linked to this pathology. These include dietary iodine deficiency \[[@R193],[@R194]\] and exposure to various environmental xenobiotics, which are important chromosome-damaging agents \[[@R195]\]. In addition, hereditary factors are also important in the etiology of thyroid cancer. The interplay of these different risk factors leads to a specific molecular pathway that results in either follicular or papillary thyroid carcinoma \[[@R191]\].

In a hospital-based case-control study on a Caucasian Portoguese population of 109 thyroid cancer patients and 217 age and gender controls, no association was found between the rs1805794 *NBN*variant and individual susceptibility toward thyroid cancer of both papillary and follicular type \[[@R191]\].

3.. META-ANALYSIS STUDIES
=========================

Since the association between *NBN* genetic variants and increased risk of cancer appear to be still inconsistent and controversial, as evidenced in the present review for the various SNPs analyzed, tumor type and ethnicity, efforts have been made toward meta-analysis studies restricted to either specific polymorphisms, as the miscoding rs1805794 which lead to the E185Q amino acid substitution, or specific tumors. The various meta-analysis studies available are herein reported.

A study, restricted to the rs1805794 *NBN* variant, was based on 16 eligible case-control studies (17 set data) comprising a total of 9734 patients and 10325 controls of mixed populations (14 studies on Caucasians, 1 on African-Americans and 2 for the Chinese population) \[[@R196]\]. The association was estimated using dominant (GC/CC vs GG), additive (CC vs GG) and recessive (CC vs CG/GG) genetic models. For the GC/CC dominant model an OR value of 1.06 (95% CI 1.00-1.12, p=0.05) was found. The effect of the rs1805794 variant was further analyzed in a stratification analysis, showing an increased risk of cancer particularly among the Caucasians (OR: 1.07; 95% CI 1.01-1.14 p=0.03) \[[@R196]\].

Concerning a possible association of the rs1805794 SNP and breast cancer risk, a systemic review and meta-analysis study was carried out based on 10 case-control eligible studies of 4452 cases and 5665 controls of mixed population (seven studies on Caucasians, two in African-Americans, and one in Asian population) \[[@R197]\]. The authors considered different genetic models: the allele contrast model (C vs G), the codominant model (CC vs GG; CG vs GG), the dominant model (CG/CC vs GG), and the recessive model (CC vs GG/CG). It was reported an OR value of 0.85 (95% CI, 0.74-0.98) for the codominant model CC vs GG, suggesting that the individuals carrying the CC genotype had a significant decreased risk to develop breast cancer, compared with those with the GG genotype. The recessive model, CC vs GG/CG, showed a borderline significant association with breast cancer, while no association was detected in subgroup analyzed for ethnicity \[[@R197]\].

In a recent systemic review and meta-analysis study, the association of the rs1805794 *NBN* variant with lung cancer risk was addressed \[[@R198]\]. Six eligible case-control studies (two studies performed among Caucasians and four studies performed among the Chinese population) were considered, for a total of 2348 lung cancer patients and 2401 cancer-free controls. The authors reported a significant risk of lung cancer development under the dominant comparison model (OR: 1.21, 95% CI, 1.07-1.37, p=000.2). In particular, subgroup analysis performed by ethnicity suggested a significant association of rs1805794 with lung cancer risk under a dominant comparison model in the Asiatic population (OR: 1.22, 95% CI, 1.06-1.41, p=0.005), but not in Caucasians (OR: 1.17, 95% CI, 0.91-1.50, p=0.220) \[[@R198]\]. OR values were not adjusted for confounding factors as age and smoking habits. Concerning the Caucasian population, the two studies included in the meta-analysis have shown either no association (343 Norwegian origin patients for non-small cell lung cancer and 413 healthy controls) \[[@R199]\] or a significant association only among a small sample of non-smoking women (OR: 2.2, 95% CI 1.0-4.8) and low-dose smoking women (OR: 4.8, 95% CI 1.5-15.7) \[[@R200]\] for the rs1805794 polymorphism.

Findings from pooled analysis and meta-analysis studies performed in Europe and in the United States, carried out on 5282 non-Latin white origin cases by the International Consortium of Bladder Cancer, clearly indicated a significant association of the rs1805794 with bladder cancer risk (OR: 1.09, 95%, CI, 1.00-1.21, P= 0.028) \[[@R201]\]. Interestingly, the strongest association was found among individuals that reported the highest smoking doses or smoking duration \[[@R201]\].

Interestingly, recent systematic reviewes and meta-analysis on the involvement of DNA repair polymorphisms in human cancers, based on the guidance "Venice criteria" for assessing cumulative epidemiologic evidence in genetic associations \[[@R202],[@R203]\], indicated an association of the rs1805794 SNP and bladder cancer risk according to the dominant model CG/CC vs GG \[[@R204]\].

4.. CONCLUSIONS
===============

Though many studies have been carried out to establish a possible association between *NBN*gene polymorphisms and increased risk of cancer, the results still remain inconclusive and sometimes contradictory (Table **[2](#T2){ref-type="table"}**).

Based on the "Venice criteria" so far strong epidemiological credibility was found for the NBN miscoding E185Q (rs1805794) variant and bladder cancer. Remarkably, the E185 aminoacid is located within the BRCT1 domain of NBN. This domain is involved in NBN interaction with BRCA1, allowing the formation of the BRCA1-associated genome surveillance complex (BASC) that is responsible for the recognition and repair of DNA DSBs \[[@R205]\].

Meta analysis studies have the advantage of collecting a large number of cases, however some of them need to be considered with caution since they are not adjusted for relevant confounders, such as age and lifestyle, in particular smoking habits. Gene-gene and gene-environmental interactions need to be taken into account in future studies, since the carcinogenic mechanisms involving alteration in DNA repair pathways are affected by exposure to environmental agents, and more relevance should be put to report about the level of exposure. It has been stressed that, whereas genotyping is accurate, environmental exposure is often classified with a high degree of uncertainty \[[@R204]\]. In addition, association studies would greatly benefit from analysis of haplotypes and combined effect of several SNPs in multiple and different genes taking part in DNA repair, since it is becoming recognized that the contribution of single variants to the genetic risk of cancer may be very modest.
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ABBREVIATIONS
=============

ALL

:    = Acute lymphoblastic leukemia

AML

:    = Acute myeloid leukemia

ATM

:    = Ataxia-Telangiectasia Mutated

bps

:    = Base pairs

BCC

:    = Basal cell carcinoma

BRCA1

:    = Breast cancer 1 protein

BRCA2

:    = Breast cancer 2 protein

BRCT

:    = BRCA1 carboxy-terminal domain

DSB

:    = DNA double-strand break

FHA

:    = Forkhead associated domain

HCC

:    = Hepatocellular carcinoma

HL

:    = Hodgkin lymphoma

HNSCC

:    = Head and neck squamous cell carcinomas

HRR

:    = Homologous recombination repair

MRN

:    = MRE11/RAD50/NBN complex

NBS

:    = Nijmegen Breakage Syndrome

NHEJ

:    = Non-homologous end-joining

NHL

:    = Non-Hodgkin lymphoma

NPC

:    = Nasopharyngeal carcinoma

RCC

:    = Renal cell carcinoma

SNP

:    = Single nucleotide polymorphism

OR

:    = Odd ratio

UV

:    = Ultraviolet

###### 

NBN Gene Polymorphisms Reported in the Paper

  ----------------------------------------------------------------------------------------------------------------------------------------------
  Database\    Polymorphism                                          Exon/intron   Amino Acid Substitution   Location in the Protein
  SNP ID                                                                                                     
  ------------ ----------------------------------------------------- ------------- ------------------------- -----------------------------------
  rs13312842   c.-905T\>C; NBS1_5(-905)T/C                           5'UTR                                   

               924T\>C[°](#T1F1){ref-type="table-fn"}                5'UTR                                   

  rs36226237   c110242delAGTA;\                                      5'UTR                                   
               NBS1_5UTR\_(-352)\_del(AGTA)                                                                  

  rs1063045    102G\>A; Ex2+65G\>A; NBSI_X2\_(102)\_G/A;             Exon 2        L34L                      FHA

  rs1805796    c.320+208G\>A                                         Intron 3                                

  rs1805794    553G \>C; 8360G\>C; EX6-32G\>C; NBSI_X5\_(553)\_G/C   Exon 5        E185Q                     BRCT1

  rs61754796   c.628G\>T                                             Exon 6        V210F                     Tandem BRCT linker region

  rs769420     797C\>T                                               Exon 7        P266L                     BRCT2

  rs1805790    c.994+1937A\>G                                        Intron 8                                

  rs867185     IVS9+1488C\>T                                         Intron 8                                

  rs2234744    c.1124+18C\>T; IVS9+18C/T                             Intron 9                                

  rs1805818    c.1124+91C\>A; ISV9+91C/A                             Intron 9                                

               30537G\>C°                                            Intron 9                                

  rs709816     c.1197T\>C                                            Exon 10       D399D                     Downstream of tandem BRCT domains

  rs2308962    c.1915-7A\>G; IVS12-7A\>G                             Intron 12                               

  rs3736639    c.2071-30A\>T                                         Intron 13                               

  rs3736640    c.2071-61A\>T; IVS13-61A/T                            Intron 13                               

  rs1061302    c.2016A\>G; NBSI_X13\_(2016)\_A/G                     Exon 13       P672P                     MRE11 binding domain

  rs1063053    c.\*273G\>A; EX17+304G\>A; NBSI_3UTR\_(+27)\_G/A      3' UTR                                  

  rs2735383    c.\*541G\>C                                           3'UTR                                   

  rs13312981   c.\*757A\>G                                           3'UTR                                   

  rs1063054    c.\*1209A\>C                                          3'UTR                                   

  rs13312986   c.\*1692A\>G                                          3'UTR                                   

  rs9995       c.\*1754T\>C                                          3'UTR                                   

  rs14448      c.\*1977T\>C                                          3'UTR                                   
  ----------------------------------------------------------------------------------------------------------------------------------------------

rs number not available in the database.

###### 

Association of Individual NBN Polymorphisms and Cancer Risk

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                    Population               n° cases              n° controls   Polymorphisms and association (OR) reported as\                                                 References
                                                                                 significant                                                                                     
  ----------------- ------------------------ --------------------- ------------- ----------------------------------------------------------------------------------------------- ------------
  Basal Cell\       Caucasian\               241\                  574\          No (rs1805794)\                                                                                 \[72\]\
  Carcinoma         Caucasian                529                   533           2.19 Men (rs1805794CC), No women (rs1805794)                                                    \[73\]

  Bladder           Caucasian\               299\                  278\          1.64 (rs1805794 CC)\                                                                            \[82\]\
                    Caucasian\               1086\                 1020\         No (rs1063045, rs1805794, rs867185, rs1063053)\                                                 \[89\]\
                    Mixed                    771                   800           No (rs14448, rs9995, rs13312986, rs1063054, rs133312981, rs2735383, rs1063053)                  \[90\]

  Breast            Caucasian\               2205\                 1826\         No (rs1063045, rs1805794, rs709816, rs1061302)\                                                 \[100\]\
                    Caucasian\               223\                  319\          No  (rs1805794)\                                                                                \[102\]\
                    Afroamerican\            766\                  681\          No  (rs1805794)\                                                                                \[101\]\
                    Caucasian\               1273\                 1136\         No  (rs1805794)\                                                                                \[101\]\
                    Chinese\                 220\                  310\          No  (rs1805794)\                                                                                \[103\]\
                    Caucasian\               336\                  416\          No  (rs1805794)\                                                                                \[104\]\
                    Afroamerican\            63\                   78\           Significant trend (rs1805794)\                                                                  \[104\]\
                    Caucasian\               97\                   74\           No  (rs1805794), 3.4 (rs36226237)\                                                              \[105\]\
                    Caucasian\               289\                  548\          No (rs1805794)\                                                                                 \[95\]\
                    Taiwanese\               559\                  1125\         No  (rs1805794)\                                                                                \[106\]\
                    Non-hispanic Caucasian   421                   423           No (rs1805794, rs1061302, rs1063045), 1.2 (rs1805790 GG)\                                       \[107\]
                                                                                 1.3 (rs1805794 GG) 1.83 (rs1805794 CC), 4.5 (rs924 CC)                                          

  Colorectal        Caucasian                532                   532           No (rs1805794)                                                                                  \[111\]

  Head and Neck     Caucasian\               175\                  275\          No (rs1063045, rs2234744, rs709816, rs1061302, rs3736639)\                                      \[116\]\
                    Chinese                  1052                  1168          1805794GC lower in laryngeal cancer\                                                            \[126\]
                                                                                 No (rs2735383)1.7 (rs1805794 CC) 3.7 (rs1805794 GC) East China\                                 
                                                                                 No (rs2735383)1.5 (rs1805794CC) 3.9 (rs1805794GC) South China                                   

  Hepatic Cancer    Chinese                  865                   900           1.4 (rs1805794 GC) 2.27 (rs1805794 CC)\                                                         \[132\]
                                                                                 No (rs2735383)                                                                                  

  Leukaemia         Caucasian\               157\                  275\          No (rs1063045, rs1805794, rs709816, rs1061302, rs2234744)\                                      \[148\]\
                    Chinese\                 175\                  360\          1.8 (rs376639 TT)\                                                                              \[65\]\
                    Chinese                  428                   600           3.4 (rs1805794 CC), No (rs2735383)\                                                             \[149\]
                                                                                 1805794 CC as reference GG e GC were associated with decreased risk of cancer, No (rs2735383)   

  Lymphoma          NI\                      91\                   154\          No (rs1063045, rs1805794, rs2234744, rs709816, rs1061302, rs2308962)\                           \[28\]\
                    Mixed\                   797\                  793\          No (rs13312842, rs36226237, rs1805796, rs1063053, rs1063045, rs1805794, rs1061302)\             \[145\]\
                    Mixed                    200                   220           No (rs1805794)                                                                                  \[146\]

  Lung              Mixed\                   611\                  1040\         1.6 (rs1061302GG), 1.6 (rs1063054)\                                                             \[160\]\
                    Chinese\                 1559\                 1679\         No (rs14448,13312986) 1.4 (rs2735383 CC recessive model)\                                       \[64\]\
                    Caucasian\               343\                  413\          1.7  (rs2735383 CC recessive model for never smokers)\                                          \[199\
                    Caucasian                177                   154           No (rs1805794)\                                                                                 \[200\]
                                                                                 2.2 non-smoking women, 1.5 low-dose smoking women\                                              
                                                                                 (rs 805794)                                                                                     

  Medulloblastoma   NI                       42 tumor samples      \-            No (rs1063045, rs709816, rs1061302, rs1805794, rs2234744, rs1805818, rs2308962, rs3736640)      \[168\]

  Melanoma          Caucasian                632                   615           No (rs9995, rs867185, rs1063045)                                                                \[37\]

  Ovarian           Caucasian                643-732               1246-1695     No (rs1063045, rs1805794, rs769420, rs1061302)                                                  \[182\]

  Prostate          Caucasian\               200\                  200\          No (rs1805794)\                                                                                 \[57\]\
                    Caucasian                239 early cancer\     NI            No (rs1805794)\                                                                                 \[186\]
                                             186 advanced cancer                 1.8 (rs1805794 GG)                                                                              

  Renal Cell\       Caucasian                326                   335           2.13 (rs1805794 CC)                                                                             \[190\]
  Carcinoma                                                                                                                                                                      

  Thyroid Cancer    Caucasian                109                   217           No (rs1805794)                                                                                  \[191\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: NI: not indicated; No: no significant association found; OR: odds ratio.

[^1]: For these two NBN variants the rs numbers are not available.
